WallStreetZenWallStreetZen

NASDAQ: TRVI
Trevi Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TRVI

Based on 6 analysts offering 12 month price targets for Trevi Therapeutics Inc

Min Forecast
$6.00-11.11%
Avg Forecast
$18.92+180.25%
Max Forecast
$29.00+329.63%

Should I buy or sell TRVI stock?

Based on 6 analysts offering ratings for Trevi Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TRVI's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TRVI as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their TRVI stock forecasts and price targets.

TRVI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-11
lockedlocked$00.00+00.00%2025-03-10
lockedlocked$00.00+00.00%2025-03-10
lockedlocked$00.00+00.00%2025-03-10
lockedlocked$00.00+00.00%2025-03-10
B. Riley Securities
Top 3%
98
Strong BuyReiterates$6.00-11.11%2024-10-07

1 of 1

Forecast return on equity

Is TRVI forecast to generate an efficient return?

Company
-105.84%
Industry
141.96%
Market
90.01%
TRVI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TRVI forecast to generate an efficient return on assets?

Company
-90.58%
Industry
32.33%
TRVI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRVI earnings per share forecast

What is TRVI's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.55
Avg 2 year Forecast
-$0.64
Avg 3 year Forecast
-$0.72

TRVI revenue forecast

What is TRVI's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$4.3M
Avg 2 year Forecast
$85.7M
Avg 3 year Forecast
$92.6M

TRVI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRVI$6.75$18.92+180.25%Strong Buy
UPB$9.61$56.50+487.93%Strong Buy
CGEM$8.79$33.50+281.11%Strong Buy
ANAB$16.73$37.33+123.15%Buy
PGEN$1.80$5.50+205.56%Buy
View Top Biotech Stocks

Trevi Therapeutics Stock Forecast FAQ

Is Trevi Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: TRVI) stock is to Strong Buy TRVI stock.

Out of 6 analysts, 3 (50%) are recommending TRVI as a Strong Buy, 3 (50%) are recommending TRVI as a Buy, 0 (0%) are recommending TRVI as a Hold, 0 (0%) are recommending TRVI as a Sell, and 0 (0%) are recommending TRVI as a Strong Sell.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.

What is TRVI's earnings growth forecast for 2025-2027?

(NASDAQ: TRVI) Trevi Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.96%.

Trevi Therapeutics's earnings in 2025 is -$44,317,000.On average, 6 Wall Street analysts forecast TRVI's earnings for 2025 to be -$41,891,812, with the lowest TRVI earnings forecast at -$52,268,683, and the highest TRVI earnings forecast at -$30,746,284. On average, 6 Wall Street analysts forecast TRVI's earnings for 2026 to be -$49,063,383, with the lowest TRVI earnings forecast at -$66,873,169, and the highest TRVI earnings forecast at -$36,895,541.

In 2027, TRVI is forecast to generate -$55,497,043 in earnings, with the lowest earnings forecast at -$76,865,711 and the highest earnings forecast at -$38,432,856.

What is TRVI's revenue growth forecast for 2027-2029?

(NASDAQ: TRVI) Trevi Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.94%.

Trevi Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TRVI's revenue for 2027 to be $330,522,557, with the lowest TRVI revenue forecast at $330,522,557, and the highest TRVI revenue forecast at $330,522,557. On average, 1 Wall Street analysts forecast TRVI's revenue for 2028 to be $6,590,466,061, with the lowest TRVI revenue forecast at $6,590,466,061, and the highest TRVI revenue forecast at $6,590,466,061.

In 2029, TRVI is forecast to generate $7,115,843,196 in revenue, with the lowest revenue forecast at $1,738,702,383 and the highest revenue forecast at $19,043,479,900.

What is TRVI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TRVI) forecast ROA is -90.58%, which is lower than the forecast US Biotechnology industry average of 32.33%.

What is TRVI's Price Target?

According to 6 Wall Street analysts that have issued a 1 year TRVI price target, the average TRVI price target is $18.92, with the highest TRVI stock price forecast at $29.00 and the lowest TRVI stock price forecast at $6.00.

On average, Wall Street analysts predict that Trevi Therapeutics's share price could reach $18.92 by Mar 11, 2026. The average Trevi Therapeutics stock price prediction forecasts a potential upside of 180.25% from the current TRVI share price of $6.75.

What is TRVI's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TRVI) Trevi Therapeutics's current Earnings Per Share (EPS) is -$0.44. On average, analysts forecast that TRVI's EPS will be -$0.55 for 2025, with the lowest EPS forecast at -$0.68, and the highest EPS forecast at -$0.40. On average, analysts forecast that TRVI's EPS will be -$0.64 for 2026, with the lowest EPS forecast at -$0.87, and the highest EPS forecast at -$0.48. In 2027, TRVI's EPS is forecast to hit -$0.72 (min: -$1.00, max: -$0.50).

What is TRVI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TRVI) forecast ROE is -105.84%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.